http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014171477-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b768a04005db7176ece59a3a9587f540 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c899e21de4af1ee13db28413188490e5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-06 |
| filingDate | 2012-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4c4c070e9188c83045689f4c3baf218 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8acd584ccdf8aa845e7340b3a10c5c61 |
| publicationDate | 2014-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2014171477-A1 |
| titleOfInvention | Derivatives of celeboxib, use thereof and preparation thereof |
| abstract | Derivatives of celecoxib that lack cyclooxygenase inhibitory activity but have improved PDE5 inhibitory activity are provided along with pharmaceutical compositions containing them for the treatment or prevention of cancer. Such compounds are expected to have reduced toxicity compared with celecoxib and other cyclooxygenase inhibitors, and greater efficacy compared with conventional PDE5 inhibitors. Derivatives of celecoxib are also suitable for treating chronic inflammatory conditions, erectile dysfunction, pulmonary hypertension, congestive heart failure, and enhancement of cognitive function. |
| priorityDate | 2011-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 788.